{"nctId":"NCT01033747","briefTitle":"Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study","startDateStruct":{"date":"2003-02"},"conditions":["Liver Iron Overload"],"count":70,"armGroups":[{"label":"Deferasirox","type":"EXPERIMENTAL","interventionNames":["Drug: Deferasirox"]},{"label":"Deferasirox Crossover","type":"EXPERIMENTAL","interventionNames":["Drug: Deferasirox"]}],"interventions":[{"name":"Deferasirox","otherNames":[]},{"name":"Deferasirox","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients Currently participating in the 9-month comparative prolongation of extension phase of the original study.\n* Patients currently participating in the food-effect sub-study, according to amendment 3.\n* Ability to provide written informed consent prior to participation in this non-comparative extension study.\n* Female patients sexually active must use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation.\n* Body weight of at least 35 kg.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding patients.\n* History of non-compliance to medical regimens and patients who are considered potentially unreliable.\n* Proteinuria \\> 300 mg/L second void morning urine.\n* Patients with serum creatinine above the upper limit normal.\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Relative Change From Baseline in Liver Iron Content (LIC) After Prolonged Use of Deferasirox","description":"The mean percentage change in liver iron content (LIC) as assessed by superconducting quantum interference device (SQUID) was evaluated by comparing the LIC at the start of Deferasirox treatment to the LIC at the end of the 5 year extension study for participants who were treated with Deferasirox for more than 3.5 years. LIC is expressed in milligrams of iron per gram of liver dry weight (mgFe/g dw). Relative change = 1- (Change in LIC from Baseline/Baseline level) x 100.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.9","spread":"47.11"},{"groupId":"OG001","value":"-23.1","spread":"33.38"}]}]}]},{"type":"SECONDARY","title":"Relative Change in Serum Ferritin From Baseline to 3.5 Years","description":"The mean percentage change in serum ferritin was evaluated by comparing the serum ferritin level at the start of Deferasirox treatment to the serum ferritin level collected 18 months following the start of the extension study. Serum ferritin is measured in micrograms per Liter. Relative Change = 1- (Change in ferritin level from Baseline/Baseline level) x 100.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":null},{"groupId":"OG001","value":"33.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":51},"commonTop":["Cough","Pyrexia","Pharyngitis","Back pain","Headache"]}}}